Tags

Type your tag names separated by a space and hit enter

Zoledronic acid: new indication. No therapeutic advantage in postmenopausal osteoporosis.
Prescrire Int. 2008 Aug; 17(96):143.PI

Abstract

In the absence of relevant comparisons, it remains to be shown whether zoledronic acid, given as a yearly intravenous infusion, has any therapeutic advantage over other bisphosphonates.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

19480098

Citation

"Zoledronic Acid: New Indication. No Therapeutic Advantage in Postmenopausal Osteoporosis." Prescrire International, vol. 17, no. 96, 2008, p. 143.
Zoledronic acid: new indication. No therapeutic advantage in postmenopausal osteoporosis. Prescrire Int. 2008;17(96):143.
(2008). Zoledronic acid: new indication. No therapeutic advantage in postmenopausal osteoporosis. Prescrire International, 17(96), 143.
Zoledronic Acid: New Indication. No Therapeutic Advantage in Postmenopausal Osteoporosis. Prescrire Int. 2008;17(96):143. PubMed PMID: 19480098.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Zoledronic acid: new indication. No therapeutic advantage in postmenopausal osteoporosis. PY - 2009/6/2/entrez PY - 2009/6/2/pubmed PY - 2009/6/13/medline SP - 143 EP - 143 JF - Prescrire international JO - Prescrire Int VL - 17 IS - 96 N2 - In the absence of relevant comparisons, it remains to be shown whether zoledronic acid, given as a yearly intravenous infusion, has any therapeutic advantage over other bisphosphonates. SN - 1167-7422 UR - https://www.unboundmedicine.com/medline/citation/19480098/Zoledronic_acid:_new_indication__No_therapeutic_advantage_in_postmenopausal_osteoporosis_ DB - PRIME DP - Unbound Medicine ER -